COMMUNIQUÉS West-GlobeNewswire

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
02/02/2026
Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today [...]
Johns Hopkins Health Plans Executive Elected Chair of Medicare Advantage Plan Alliance Compliance Forum
02/02/2026
Melissa Mohon to Lead National Organization Dedicated to Improving Regulatory Compliance and Quality Care for Medicare Beneficiaries HANOVER, Md., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Melissa L. Mohon, Executive Director [...]
DLH to Announce Fiscal 2026 First Quarter Financial Results
02/02/2026
ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
02/02/2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
02/02/2026
XanaMIA trial fully enrolled with final results expected in November 2026 SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the XanaMIA pivotal Alzheimer’s disease (AD) trial’ [...]
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
02/02/2026
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute [...]
Standard Dental Labs Announces Acquisition of BRLIT Dental Laboratory, Inc.
02/02/2026
ORLANDO, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (“SDL”), a Florida-based dental laboratory platform focused on high-quality clinical outcomes and long-term practitioner relationships, today [...]
Quotient Therapeutics Appoints Seasoned Life Sciences Executive, Susan Keefe, as Chief Financial Officer
02/02/2026
CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has appointed [...]
Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook
02/02/2026
VANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a provider of compliant digital health infrastructure and [...]
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
02/02/2026
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of [...]
The Real Ironman Economy: How AI, Superfibers, and Defense Tech Could Theoretically Converge
02/02/2026
DENVER, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Recent reports that Palantir Technologies (NASDAQ: PLTR) has been tapped by President Trump to deploy AI systems to hunt fraud, likened in headlines to an AI “Ironman suit”, [...]
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
02/02/2026
Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a [...]
Ringing in Your Ears? ASHA Shares Facts About a Common Yet Misunderstood Health Issue
02/02/2026
Association Stresses Importance of Prevention and Availability of Treatment for Tinnitus Awareness Week Rockville, Md., Feb. 02, 2026 (GLOBE NEWSWIRE) -- As many as one in three people globally have experienced tinnitus [...]
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
02/02/2026
Product is currently under review with the FDA Potential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative [...]
BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism
02/02/2026
Somerville, MA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Improving social communication skills in children with autism has traditionally relied on structured teaching approaches and stable support environments. With the [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
02/02/2026
COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount [...]
CROSSJECT annonce l’initiation de couverture de son titre par Portzamparc (Groupe BNP Paribas)
02/02/2026
CROSSJECT annonce l’initiation de couverture de son titre par Portzamparc (Groupe BNP Paribas) DIJON, France - 02 février 2026 (07h15CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), la société pharmaceutique de [...]
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)
02/02/2026
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) DIJON, France - February 2, 2026 (7:15 a.m. CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , the specialty pharmaceutical [...]
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
02/02/2026
Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful efficacy in patients [...]

Pages